

## SUPPLEMENTARY APPENDIX

## Appendix

**Table S1.** Patient characteristics in patients with incident stage IIIB–IV NSCLC at diagnosis

	All N=2119	NSQ NSCLC n=666	SQ NSCLC n=396	NSCLC NOS n=315	NSCLC without histological confirmatio n n=693
<b>Median age (IQR) at diagnosis, years</b>	72.0 (64–80)	69.0 (61–76)	70.0 (63–77)	69.0 (61–76)	79.0 (71–84)
<b>WHO PS, n (%)</b>					
0–1	662 (31.2)	302 (45.3)	177 (44.7)	121 (38.4)	37 (5.3)
2	414 (19.5)	159 (23.9)	111 (28.0)	57 (18.1)	73 (10.5)
3–4	848 (40.0)	157 (23.6)	81 (20.5)	99 (31.4)	502 (72.4)
Missing/unknown	195 (9.2)	48 (7.2)	<30	38 (12.1)	81 (11.7)
<b>Brain metastases, n (%)</b>	191 (9.0)	49 (7.4)	27 (6.8)	27 (8.6)	79 (11.4)
<b>SACT treatment received after diagnosis, n (%)</b>					
No SACT treatment	1471 (69.4)	366 (55.0)	216 (54.6)	201 (63.8)	668 (96.4)
At least one line of therapy	648 (30.6)	300 (45.0)	180 (45.5)	114 (36.2)	25 (3.6)

IQR, interquartile range; NOS, not otherwise specified; NSCLC, non-small cell lung cancer;

NSQ, non-squamous; PS, performance status; SACT, systemic anti-cancer therapy; SQ,

squamous; WHO, World Health Organization.